Aigen Investment Management LP Has $310,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Aigen Investment Management LP lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,989 shares of the medical device company’s stock after selling 1,222 shares during the quarter. Aigen Investment Management LP’s holdings in DexCom were worth $310,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in DexCom in the 4th quarter valued at approximately $5,812,000. M&T Bank Corp raised its position in DexCom by 2.5% in the 4th quarter. M&T Bank Corp now owns 37,780 shares of the medical device company’s stock valued at $2,939,000 after buying an additional 937 shares during the last quarter. Atria Investments Inc raised its position in DexCom by 13.4% in the 4th quarter. Atria Investments Inc now owns 17,379 shares of the medical device company’s stock valued at $1,352,000 after buying an additional 2,059 shares during the last quarter. Keybank National Association OH grew its stake in DexCom by 101.4% in the fourth quarter. Keybank National Association OH now owns 17,585 shares of the medical device company’s stock valued at $1,368,000 after purchasing an additional 8,853 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI bought a new position in DexCom in the fourth quarter valued at approximately $225,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $77.84 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock’s fifty day moving average price is $84.83 and its two-hundred day moving average price is $76.99. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $30.42 billion, a price-to-earnings ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock valued at $3,309,794 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DXCM. Canaccord Genuity Group upped their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company upped their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Finally, Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.